Hyderabad: The phase-2 clinical trial of the indigenously developed Covaxin began on Tuesday in Nagpur.
Bharat Biotech, the Hyderabad-based firm behind it, is testing the vaccine at Nagpur’s Gillurkar Hospital. In the first phase, 55 volunteers had undergone the test.
None of the volunteers reported any complication after the first dose. The vaccine trial will continue with a gap of 28 days, 42 days, 104 days and 194 days. The blood samples will be checked for growth in antibodies after each dose.
